Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists.

British journal of biomedical science·2026
Same author

Immunohistochemical Assay Variability and Human Epidermal Growth Factor Receptor 2 (HER2)-Low Breast Cancer Detection: A Laboratory Comparison in the Netherlands.

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Solving the Puzzle of Hans' Algorithm (HA) Methodological Shortcomings: Canadian Harmonization of Hans' Algorithm for Diffuse Large B-Cell Lymphoma (DLBCL) and Development of Fit-for-Purpose Modified Hans' Algorithm (mHA).

Applied immunohistochemistry & molecular morphology : AIMM·2026
Same author

Computer-Aided Quantitative Image Analysis of Multiple Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Assays in Breast Carcinoma.

Archives of pathology & laboratory medicine·2026
Same author

Understanding general practice veterinarians' confidence in identifying and treating avian influenza.

The Veterinary record·2026
Same author

Understanding sheep lameness management in relation to culling and the UK five-point plan.

Animal welfare (South Mimms, England)·2026

相关实验视频

Updated: Jan 17, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.0K

低HER2测试的新标准:CASI-01比较方法研究

David J Dabbs1, Emina Torlakovic2, Søren Nielsen3

  • 1CASI Steering Committee Member, USA; Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

EBioMedicine
|September 13, 2025
PubMed
概括

准确的HER2测试对于Trastuzumab deruxtecan (T-Dxd) 的资格至关重要. 增强的免疫组织化学 (IHC) 灵敏度和图像分析改善了对HER2低表达的检测,解决了当前测试的局限性.

关键词:
分析敏感度 分析敏感度校准 校准 校准 校准 校准 校准动态范围 动态范围在HER2中,HER2是HER2.免疫组织化学 免疫组织化学

更多相关视频

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

689
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
10:21

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

Published on: December 25, 2017

14.2K

相关实验视频

Last Updated: Jan 17, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

13.0K
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

689
Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
10:21

Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation

Published on: December 25, 2017

14.2K

科学领域:

  • 在瘤学瘤学.
  • 病理学 病理学 病理学
  • 生物标志物检测检测 生物标志物检测

背景情况:

  • 目前对HER2过度表达的免疫组织化学 (IHC) 测定不足以检测Trastuzumab deruxtecan (T-Dxd) 资格所需的HER2低表达.
  • 针对HER2蛋白表达,没有任何低HER2测定得到验证,这在T-Dxd患者选择中造成了关键差距.

研究的目的:

  • 为了确定精确的HER2测试的最佳测定条件,区分HER2过度表达 (3+) 和HER2低 (1+/超低) 表达.
  • 为了比较传统的FDA批准的HER2测定与使用病理学家和图像分析读数的更高灵敏度测定.

主要方法:

  • 这项CASI-01研究涉及欧洲和美国的54个IHC实验室.
  • HER2过度表达被证实与HER2基因放大使用in situ杂交 (ISH).
  • 使用新的 HER2 参考标准和动态范围参数来评估 HER2 低精度.

主要成果:

  • 预测HER2试验显示检测值 (30,000-60,000分子/细胞) 的变化,但对HER2过度表达 (3+) 的高精度.
  • 这些测试表明检测HER2-低得分的动态范围较差.
  • 通过图像分析提高IHC灵敏度,提高了HER2低分数检测的6倍 (p=0.0017).

结论:

  • 标准IHC测定准确地识别HER2 3+,但缺乏精确HER2-低得分的动态范围.
  • 增强的IHC分析灵敏度与图像分析相结合,对于准确的HER2-低测试至关重要.
  • 这项研究强调了报告IHC分析灵敏度和测试动态范围的重要性,以及图像分析在精准医学中的潜力.